Aerin Medical today touted one-year results from a trial evaluating the safety and efficacy of its RhinAer system in those with chronic rhinitis.
Sunnyvale, Calif.-based Aerin designed RhinAer as a temperature-controlled radiofrequency technology used to disrupt nerve signals that cause chronic rhinitis symptoms.
According to a news release, the study demonstrated that, following a single RhinAer treatment, symptom severity significantly decreased in the first two weeks and remained low through the one-year follow-up. Results were published in the American Journal of Rhinology & Allergy.
The prospective, single-arm, multi-center study enrolled 50 adult patients with moderate to severe rhinitis symptoms and monitored them at two, four, 12, 26 and 52 weeks following RhinAer treatment. It met its primary endpoint in demonstrating clinically significant symptom reduction three months after treatment, with lasting improvements observed at one year.
No serious device- or procedure-related adverse events occurred as the treatment was well tolerated, with authors noting that no related headaches were reported throughout the trial. Additionally, subgroup analysis highlighted effectiveness in providing symptom relief to patients presenting with both allergic and non-allergic rhinitis.
“Historically, options have been limited for the large percentage of chronic rhinitis patients unresponsive to medication,” Aerin Medical CEO Matt Brokaw said in the release. “RhinAer provides otolaryngologists an effective, non-invasive solution for appropriately selected chronic rhinitis patients who have been challenging to treat, and fits seamlessly into any practice setting.”